Citigroup Inc Seres Therapeutics, Inc. Transaction History
Citigroup Inc
- $190 Billion
- Q1 2025
A detailed history of Citigroup Inc transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 215 shares of MCRB stock, worth $2,279. This represents 0.0% of its overall portfolio holdings.
Number of Shares
215
Previous 3,679
94.16%
Holding current value
$2,279
Previous $3,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding MCRB
# of Institutions
65Shares Held
39.5MCall Options Held
103KPut Options Held
53K-
Flagship Pioneering Inc. Cambridge, MA23.1MShares$245 Million6.86% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.09MShares$64.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.76MShares$18.7 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.62MShares$17.2 Million0.0% of portfolio
-
Ubs Group Ag1.46MShares$15.4 Million0.0% of portfolio
About Seres Therapeutics, Inc.
- Ticker MCRB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,072,000
- Market Cap $1.32B
- Description
- Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...